{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:14:46Z","timestamp":1762179286900,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ijtb.2022.11.004","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T07:38:20Z","timestamp":1669880300000},"page":"361-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Correlating clinical breakpoint concentration of moxifloxacin with gyrA mutations using the GenoType MTBDRsl assay Version 2.0"],"prefix":"10.1016","volume":"70","author":[{"given":"Zeeshan","family":"Sidiq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hanif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaushal Kumar","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal Kishore","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwani","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.K.","family":"Vashishat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijtb.2022.11.004_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006914","article-title":"Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"4","author":"Johnston","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ijtb.2022.11.004_bib2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(10)70139-0","article-title":"Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis","volume":"10","author":"Caminero","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijtb.2022.11.004_bib3","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1183\/09031936.00073611","article-title":"WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update","volume":"38","author":"Falzon","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijtb.2022.11.004_bib4","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1128\/JCM.02501-08","article-title":"Quantitative drug susceptibility testing of mycobacterium tuberculosis by use of MGIT 960 and epicenter instrumentation","volume":"47","author":"Springer","year":"2009","journal-title":"J Clin Microbiol"},{"issue":"11","key":"10.1016\/j.ijtb.2022.11.004_bib5","first-page":"1320","article-title":"Mechanisms of drug resistance in Mycobacterium tuberculosis [state of the art series. Drug-resistant tuberculosis. Edited by CY. Chiang. Number 1 in the series]","volume":"13","author":"Zhang","year":"2009","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.ijtb.2022.11.004_bib6","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/j.1469-0691.2011.03551.x","article-title":"The ins and outs of Mycobacterium tuberculosis drug susceptibility testing","volume":"17","author":"Bottger","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijtb.2022.11.004_bib7","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1128\/JCM.01257-15","article-title":"Diagnostic performance of the New version (v2.0) of GenoType MTBDRsl assay for detection of resistance to fluoroquinolones and second-line injectable drugs: a multicenter study","volume":"53","author":"Tagliani","year":"2015","journal-title":"J Clin Microbiol"},{"year":"2017","series-title":"Technical report on the critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis (WHO\/CDS\/TB\/2018.5) [Internet]","key":"10.1016\/j.ijtb.2022.11.004_bib8"},{"year":"2018","series-title":"Technical report on the pharmacokinetics and pharmacodynamics (PK\/PD) of medicines used in the treatment of drug-resistant tuberculosis (WHO\/CDS\/TB\/2018.6) [Internet]","key":"10.1016\/j.ijtb.2022.11.004_bib9"},{"issue":"2","key":"10.1016\/j.ijtb.2022.11.004_bib10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/jac\/dkv360","article-title":"Specific gyrA gene mutations predict poor treatment outcome in MDR-TB","volume":"71","author":"Rigouts","year":"2015","journal-title":"J Antimicrob Chemother"},{"year":"2014","series-title":"Mycobacteriology Laboratory Manual, Global Laboratory Initiative Advancing TB Diagnosis","author":"Stinson","key":"10.1016\/j.ijtb.2022.11.004_bib11"},{"key":"10.1016\/j.ijtb.2022.11.004_bib12","unstructured":"Ajbani K, Nikam C, Kazi M, et\u00a0al. Evaluation of GenoType MTBDRsl assay to detect drug resistance associated with fluoroquinolones, aminoglycosides and ethambutol on clinical sediments. PLoS One."},{"key":"10.1016\/j.ijtb.2022.11.004_bib13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1128\/JCM.40.1.150-154.2002","article-title":"Multicenter evaluation of fully automated BACTEC mycobacteria growth indicator tube 960 system for susceptibility testing of Mycobacterium tuberculosis","volume":"40","author":"Bemer","year":"2002","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijtb.2022.11.004_bib14","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1183\/09031936.00073611","article-title":"WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update","volume":"38","author":"Falzon","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijtb.2022.11.004_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006914","article-title":"Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"4","author":"Johnston","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ijtb.2022.11.004_bib16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(10)70139-0","article-title":"Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis","volume":"10","author":"Caminero","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijtb.2022.11.004_bib17","unstructured":"WHO- the use of molecular line probe assays for the detection of resistance to second line anti-tuberculosis drugs [Internet]. Available from: http:\/\/www.who.int\/tb\/publications\/policy-guidance-molecular-line\/en\/."},{"issue":"6","key":"10.1016\/j.ijtb.2022.11.004_bib18","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1128\/JCM.00051-16","article-title":"Performance of the New version (v2.0) of the GenoType MTBDRsl test for detection of resistance to second line drugs in multidrug-resistant Mycobacterium tuberculosis complex strains","volume":"54","author":"Brossier","year":"2016","journal-title":"J Clin Microbiol"},{"issue":"3","key":"10.1016\/j.ijtb.2022.11.004_bib19","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1128\/JCM.01865-16","article-title":"Evaluation of the GenoType MTBDR sl version 2.0 assay for second line drug resistance detection of Mycobacterium tuberculosis isolates in South Africa","volume":"55","author":"Gardee","year":"2017","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.ijtb.2022.11.004_bib20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.5588\/ijtld.17.0663","article-title":"Diagnostic accuracy of GenoType\u00ae MTBDRsl VER 2.0 in detecting second line drug resistance to M. tuberculosis","volume":"22","author":"Yadav","year":"2018","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.ijtb.2022.11.004_bib21","doi-asserted-by":"crossref","first-page":"e00279","DOI":"10.1128\/AAC.00279-19","article-title":"Fluoroquinolones in drug-resistant tuberculosis: culture conversion and pharmacokinetic\/pharmacodynamic target attainment to guide dose selection","volume":"63","author":"Al-Shaer","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2022.11.004_bib22","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ijtb.2022.11.004_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049433","article-title":"Evaluation of genotype MTBDRsl assay to detect drug resistance associated with fluoroquinolones, aminoglycosides and ethambutol on clinical sediments","volume":"7","author":"Ajbani","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijtb.2022.11.004_bib24","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.3389\/fmicb.2018.02265","article-title":"Evaluation of genotype MTBDRplus and MTBDRsl assays for rapid detection of drug resistance in extensively drug-resistant Mycobacterium tuberculosis isolates","volume":"9","author":"Hasnain","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijtb.2022.11.004_bib25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jmii.2015.04.003","article-title":"Second-line anti-tuberculosis drug resistance and its genetic determinants in multidrug-resistant Mycobacterium tuberculosis clinical isolates","volume":"49","author":"Baku\u0142a","year":"2016","journal-title":"J Microbiol Immunol Infect"},{"issue":"5","key":"10.1016\/j.ijtb.2022.11.004_bib26","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1128\/JCM.01947-09","article-title":"Detection by genotype MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug- resistant Mycobacterium tuberculosis complex isolate","volume":"48","author":"Brossier","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijtb.2022.11.004_bib27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tube.2014.11.003","article-title":"Correlating minimum inhibitory concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay","volume":"95","author":"Kambli","year":"2015","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ijtb.2022.11.004_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.meegid.2018.12.030","article-title":"Macro-geographical specificities of the prevailing tuberculosis epidemic as seen through SITVIT2, an updated version of the Mycobacterium tuberculosis genotyping database","volume":"72","author":"Couvin","year":"2019","journal-title":"Infect Genet Evol"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570722001858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570722001858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:24:52Z","timestamp":1762176292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019570722001858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0019570722001858"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2022.11.004","relation":{},"ISSN":["0019-5707"],"issn-type":[{"type":"print","value":"0019-5707"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlating clinical breakpoint concentration of moxifloxacin with gyrA mutations using the GenoType MTBDRsl assay Version 2.0","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijtb.2022.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}